Tuesday September 17, 2019 18:11

Heathcare Press Release : 03 Sep 2019

Strekin AG Secures Financing to Complete Development of STR001 in Sudden Sensorineural Hearing Loss Heathcare—03 Sep 19

Strekin AG (www.strekin.com), a clinical stage biopharmaceutical company, announced today that it has successfully closed a Series A financing round totaling CHF 2.82 Million from private investors. These funds will enable Strekin to conclude its ongoing

Polpharma Biologics Announces Global Commercialization Deal for Biosimilar Natalizumab, a Key Heathcare—03 Sep 19

Polpharma Biologics S.A. ("Polpharma Biologics") today announces that it has entered a global commercialization agreement with Sandoz AG for a natalizumab biosimilar. The medicine is currently in Phase III clinical development for the treatment of

International Atherosclerosis Society Residual Risk Reduction Initiative Publish Consensus Heathcare—03 Sep 19

A new highly selective treatment, a peroxisome proliferator-activated receptor alpha modulator (SPPARM-alpha) agonist, may help to address the gap in managing the residual risk of heart attacks and strokes in high-risk patients, according to over 50

Children#s Lives Will be Saved Due to Invention of Simple Water Treatment System Aquatabs Heathcare—03 Sep 19

The world famous medical journal The Lancet has published the results of a two year health impact trial in Bangladesh. Less than 5% of studies submitted to this peer reviewed journal are published. In this trial, the impact of using "Aquatabs Flo" at